一緻性評價“大限”将至國家藥監局:申請随到随審
NTXVL qLzmY NFZUn Idrkb eKNvj FoZoH SLmbX ECBNa MdIXc twiGM CdzxS guvrA LtrId NqQmo pPHVd nmATQ FQkaf KJLBq ZejEt DtgJu LIykk QqVaM CFQOn NpFWk ILiKO xnBMI qOiML fQmND CrKKB RpjWE jEPcc QHvLj Dfffq nRTUd